Resona Asset Management Co. Ltd. Raises Position in CVS Health Corporation $CVS

Resona Asset Management Co. Ltd. lifted its position in shares of CVS Health Corporation (NYSE:CVS) by 1.6% during the first quarter, HoldingsChannel reports. The fund owned 415,595 shares of the pharmacy operator’s stock after acquiring an additional 6,396 shares during the quarter. Resona Asset Management Co. Ltd.’s holdings in CVS Health were worth $29,727,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also recently added to or reduced their stakes in CVS. Sei Investments Co. raised its position in CVS Health by 17.4% in the second quarter. Sei Investments Co. now owns 905,715 shares of the pharmacy operator’s stock worth $62,474,000 after acquiring an additional 134,535 shares in the last quarter. The Manufacturers Life Insurance Company boosted its position in shares of CVS Health by 1.2% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 1,121,377 shares of the pharmacy operator’s stock worth $77,353,000 after purchasing an additional 13,329 shares in the last quarter. Treasurer of the State of North Carolina grew its stake in shares of CVS Health by 1.3% during the 2nd quarter. Treasurer of the State of North Carolina now owns 585,073 shares of the pharmacy operator’s stock worth $40,358,000 after purchasing an additional 7,588 shares during the period. HUB Investment Partners LLC increased its holdings in shares of CVS Health by 25.0% in the 2nd quarter. HUB Investment Partners LLC now owns 15,063 shares of the pharmacy operator’s stock valued at $1,039,000 after purchasing an additional 3,011 shares in the last quarter. Finally, Alliancebernstein L.P. lifted its stake in shares of CVS Health by 8.0% in the second quarter. Alliancebernstein L.P. now owns 1,609,404 shares of the pharmacy operator’s stock valued at $111,017,000 after purchasing an additional 119,439 shares during the period. Institutional investors and hedge funds own 80.66% of the company’s stock.

CVS Health Trading Down 1.7%

NYSE CVS opened at $102.69 on Friday. The company has a market cap of $131.03 billion, a P/E ratio of 45.24, a P/E/G ratio of 1.02 and a beta of 0.61. CVS Health Corporation has a 12 month low of $58.50 and a 12 month high of $106.15. The company has a debt-to-equity ratio of 0.78, a current ratio of 0.87 and a quick ratio of 0.66. The company has a 50-day moving average of $96.50 and a 200-day moving average of $84.03.

CVS Health (NYSE:CVS) last released its earnings results on Wednesday, May 6th. The pharmacy operator reported $2.57 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.21 by $0.36. CVS Health had a net margin of 0.72% and a return on equity of 11.88%. The business had revenue of $100.43 billion for the quarter, compared to analysts’ expectations of $94.99 billion. During the same period last year, the company earned $2.25 earnings per share. The company’s quarterly revenue was up 6.2% on a year-over-year basis. CVS Health has set its FY 2026 guidance at 7.300-7.500 EPS. As a group, equities analysts predict that CVS Health Corporation will post 7.44 earnings per share for the current year.

Insider Buying and Selling at CVS Health

In other news, Director Larry Robbins sold 370,462 shares of the business’s stock in a transaction on Thursday, May 21st. The shares were sold at an average price of $93.45, for a total transaction of $34,619,673.90. Following the completion of the sale, the director directly owned 4,824,799 shares of the company’s stock, valued at $450,877,466.55. The trade was a 7.13% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, EVP Tilak Mandadi sold 69,551 shares of the stock in a transaction on Friday, May 8th. The stock was sold at an average price of $89.58, for a total value of $6,230,378.58. Following the completion of the transaction, the executive vice president directly owned 10,133 shares in the company, valued at $907,714.14. This trade represents a 87.28% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 3,441,551 shares of company stock valued at $323,703,977 over the last three months. Corporate insiders own 0.85% of the company’s stock.

Analyst Upgrades and Downgrades

CVS has been the topic of a number of research analyst reports. JPMorgan Chase & Co. boosted their price objective on shares of CVS Health from $101.00 to $111.00 and gave the stock an “overweight” rating in a report on Tuesday, May 12th. Wall Street Zen upgraded shares of CVS Health from a “hold” rating to a “buy” rating in a research report on Tuesday. Barclays boosted their price target on CVS Health from $101.00 to $106.00 and gave the stock an “overweight” rating in a research note on Tuesday, May 26th. UBS Group upped their price target on CVS Health from $100.00 to $115.00 and gave the stock a “buy” rating in a report on Monday, June 8th. Finally, Cantor Fitzgerald raised their price objective on CVS Health from $100.00 to $110.00 and gave the company an “overweight” rating in a research note on Tuesday. Twenty-one investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat, CVS Health presently has an average rating of “Moderate Buy” and a consensus price target of $102.84.

Trending Headlines about CVS Health

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: CVS drew bullish attention after Jim Cramer highlighted health insurance/managed care as a strong sector and called CVS one of the biggest winners as Walgreens fades, reinforcing the market’s view that CVS may benefit from industry consolidation. Cramer’s Stop Trading: CVS Health
• Positive Sentiment: CVS CEO comments that Aetna has medical costs “under control” ahead of second-quarter earnings suggest margin pressure may be manageable, which could support investor confidence going into results. CVS CEO says Aetna has a handle on medical costs in advance of Q2 earnings
• Positive Sentiment: Heavy call-option buying and multiple articles flagging CVS as a momentum/trending stock point to increased trader interest and possible speculation on further upside. Here’s Why CVS Health (CVS) is a Strong Momentum Stock
• Neutral Sentiment: CVS also continued to get publicity around its Specialty Pharmacy and HIV-treatment support programs, which helps the company’s long-term image but is unlikely to move the stock immediately. HIV Is Now a Manageable Chronic Condition – How CVS Specialty Helps Patients Start and Stay on Treatment
• Negative Sentiment: A major risk factor is the reported $440 million Justice Department settlement involving CVS and Omnicare, which could weigh on sentiment by reminding investors of legal and regulatory overhangs. CVS, Omnicare reach $440M Justice Department settlement
• Negative Sentiment: A market-wrap note showing CVS trading lower on the day indicates investors are still taking profits or staying cautious ahead of earnings and settlement-related headlines. CVS Health (CVS) Stock Declines While Market Improves: Some Information for Investors

About CVS Health

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.